Probiotics are employed in therapeutic settings and for consumers who are typically healthy. However, probiotic intake can have both hypothetical and real negative effects. Probiotics should be used safely and effectively, which calls for clear, doable suggestions on how to proceed in light of the introduction of new probiotic strains and products as well as the expansion of their usage among vulnerable groups. The International Scientific Association for Probiotics and Prebiotics called a meeting to discuss and develop evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the necessity of adverse event reporting related to probiotic use, and the importance of probiotic product quality to match the needs of vulnerable populations. In the present review we focused the ICMR- DBT guidelines for the evaluation of the probiotics and current regulatory status with reference to the probiotics.